Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits

Autor: Izzo, Nicholas J., Staniszewski, Agnieszka, To, Lillian, Fa, Mauro, Teich, Andrew Franklin, Saeed, Faisal, Wostein, Harrison, Walko III, Thomas, Vaswani, Anisha, Wardius, Meghan, Ravenscroft, Jessica, Mozzoni, Kelsie, Silky, Colleen, Rehak, Courtney, Yurko, Raymond, Finn, Patricia, Look, Gary, Rishton, Gilbert, Safferstein, Hank, Miller, Miles, Johanson, Conrad, Stopa, Edward, Windisch, Manfred, Hutter-Paier, Birgit, Shamloo, Mehrdad, Arancio, Ottavio, LeVine III, Harry, Catalano, Susan M.

Synaptic dysfunction and loss caused by age-dependent accumulation of synaptotoxic beta amyloid (Abeta) 1–42 oligomers is proposed to underlie cognitive decline in Alzheimer's disease (AD). Alterations in membrane trafficking induced by Abeta oligo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e84ebf3eedb977e22810d917c677f51f

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity

Autor: Izzo, Nicholas J., Xu, Jinbin, Zeng, Chenbo, Kirk, Molly J., Mozzoni, Kelsie, Silky, Colleen, Rehak, Courtney, Yurko, Raymond, Look, Gary, Rishton, Gilbert, Safferstein, Hank, Cruchaga, Carlos, Goate, Alison, Cahill, Michael A., Arancio, Ottavio, Mach, Robert H., Craven, Rolf, Head, Elizabeth, LeVine III, Harry, Spires-Jones, Tara L., Catalano, Susan M.

Amyloid beta (Abeta) 1–42 oligomers accumulate in brains of patients with Mild Cognitive Impairment (MCI) and disrupt synaptic plasticity processes that underlie memory formation. Synaptic binding of Abeta oligomers to several putative receptor pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::291a4cf1752b6ec581a4130322d5b5d3

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.

Autor: Izzo NJ; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Staniszewski A; Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America., To L; Stanford University Medical School Behavioral and Functional Neuroscience Laboratory, Palo Alto, California, United States of America., Fa M; Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America., Teich AF; Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America., Saeed F; Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America., Wostein H; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Walko T 3rd; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Vaswani A; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Wardius M; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Syed Z; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Ravenscroft J; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Mozzoni K; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Silky C; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Rehak C; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Yurko R; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Finn P; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Look G; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Rishton G; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Safferstein H; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America., Miller M; Department of Pathology and Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America., Johanson C; Department of Pathology and Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America., Stopa E; Department of Pathology and Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America., Windisch M; NeuroScios, GmbH, Graz, Austria., Hutter-Paier B; QPS Austria GmbH, Grambach, Austria., Shamloo M; Stanford University Medical School Behavioral and Functional Neuroscience Laboratory, Palo Alto, California, United States of America., Arancio O; Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America., LeVine H 3rd; Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States of America., Catalano SM; Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.

Publikováno v: PloS one [PLoS One] 2014 Nov 12; Vol. 9 (11), pp. e111898. Date of Electronic Publication: 2014 Nov 12 (Print Publication: 2014).